Last reviewed · How we verify
Oxybuprocaine/fluorescein SDU
Oxybuprocaine/fluorescein SDU is a local anesthetic and a fluorescent dye used to visualize the corneal endothelium.
Oxybuprocaine/fluorescein SDU is a local anesthetic and a fluorescent dye used to visualize the corneal endothelium. Used for Assessment of corneal endothelial function and morphology.
At a glance
| Generic name | Oxybuprocaine/fluorescein SDU |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Local anesthetic |
| Target | Sodium channels |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Oxybuprocaine is a local anesthetic that works by blocking sodium channels in nerve fibers, preventing the transmission of pain signals. Fluorescein is a fluorescent dye that stains the corneal endothelium, allowing for visualization of the corneal endothelial cells. The combination of oxybuprocaine and fluorescein is used to assess corneal endothelial function and morphology.
Approved indications
- Assessment of corneal endothelial function and morphology
Common side effects
- Corneal toxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybuprocaine/fluorescein SDU CI brief — competitive landscape report
- Oxybuprocaine/fluorescein SDU updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI